ZNF2

Across TCGA pan-cancer cohorts, ZNF2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF2 data layer compared with 29 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZNF2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF2 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

LUAD, GBM, and HNSC are the cancer types where ZNF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.303	0.940	.013	13	view →
GBM	OS	Median	All	0.950	0.773	.018	3	view →
HNSC	DFS	Median	All	1.000	0.770	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZNF2–LUAD (OS)

Open the LUAD breakdown →